RPG Life Sciences Limited
RPGLIFE · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹1,793.38.
Piotroski F-score 4/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%20.3%
- ✓Low debt (D/E < 0.5)0.03x
- ✕Positive free cash flow
- ✓Revenue growth > 10%24%
- ✕Earnings growing-75%
- ✓Net margin ≥ 10%16.3%
- ✓Current ratio > 1.53.48
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 13.53
- ✕Piotroski ≥ 74/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Strong return on equity (20.3%).
- •Lightly leveraged balance sheet.
- •Healthy profit margin (16.3%).
- •Financially solid — Altman Z 13.53.
Opportunities
- •Revenue growing (24% YoY).
Threats
- •Earnings contracting year on year.
About RPG Life Sciences Limited
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage form
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.